PROFNAIT is a collaborative project that involves nine of the leading Northern European companies, universities and health care institutions within FNAIT prevention and therapy.
The goal of the PROFNAIT project is to develop a new drug that can protect HPA-1a negative women from being immunized against HPA-1a and prevent the development of FNAIT. The project also aims at preparing the country-wide screens of pregnant women that are required in order to identify the women who would benefit from prophylaxis.
The project is divided into three stages:
- Collection of plasma from women who are already immunized against HPA-1a. This plasma is required to make the drug. We will need to collect plasma from hundreds of HPA-1a immunized women and we encourage all potential doners to sign up.
- In the second phase, we will show that the drug is both safe and effective. Firstly, we will see how well it works in healthy men; secondly, we will screen 85,000 pregnant women for HPA-1a status and invite the 1,600 HPA-1a negative women that we expect to find to participate in the final testing.
- In the last phase, we will seek approval of the drug and prepare for the implementation of HPA-1a typing and prophylaxis worldwide.